clinical trial · NCT04268498
A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma
University of Miami·phase2·active not recruiting·n = 310
Multiple MyelomaBortezomibDexamethasoneLenalidomideAcetaminophenDiphenhydramineMontelukastCarfilzomibDaratumumab
brief summary
This study is being done to find out whether carfilzomib, lenalidomide, and dexamethasone (KRD) or KRD and Daratumumab (KRD+DARA) might be safer and more effective ways of controlling multiple myeloma than the standard of care treatment, which is lenalidomide, bortezomib, and dexamethasone (VRD).
started
Feb 11, 2020
primary completion
Feb 1, 2027
completion
Feb 1, 2027
last updated
Mar 24, 2026
detailed description
Per protocol amendment version 4.0 (May 23, 2022), Arm A will be closed and no additional participants will be enrolled in this arm.
official title
Phase 2, Open-Label Randomized Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone vs Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol